CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.94B, above the global median of $1.15B
- PositionOperating margin is 48.4%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations18 currently firing — 18
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.36%
Annual Rate
CNY 1.20Paid semi-annual
Payout Ratio
16.8%Sustainable
Payback Period
73.4 yr
Last Ex-Dividend
Sep 2, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
39.65BCNY5.94B · vs all stocks (USD)
Trailing P/E
14.23xvs Biotechnology peers
Revenue (TTM)
6.13BCNY919.21M · vs all stocks (USD)
Profit Margin
43.67%vs Biotechnology peers
Beta
0.0020xvs all stocks
52-Week Change
-22.17%vs all stocks
Forward Annual Dividend Yield
1.36%vs all stocks
Market Capitalization
39.65BCNY5.94B · vs all stocks (USD)
Enterprise Value
33.79BCNY5.06B · vs all stocks (USD)
Trailing P/E
14.23xvs Biotechnology peers
Forward P/E
11.62xvs Biotechnology peers
Price to Sales (TTM)
6.20xvs Biotechnology peers
Price to Book (MRQ)
4.49xvs Biotechnology peers
Enterprise to Revenue
5.51xvs Biotechnology peers
Enterprise to EBITDA
12.47xvs Biotechnology peers
Gross Margin
94.80%vs Biotechnology peers
Profit Margin
43.67%vs Biotechnology peers
Operating Margin
48.42%vs Biotechnology peers
Return on Assets (TTM)
20.29%vs Biotechnology peers
Return on Equity (TTM)
36.71%vs Biotechnology peers
Revenue (TTM)
6.13BCNY919.21M · vs all stocks (USD)
Revenue per Share (TTM)
13.60CNYUpdated Oct 24, 2026Quarterly Revenue Growth
36.10%vs Biotechnology peers
Gross Profit (TTM)
5.87BCNY880.09M · vs all stocks (USD)
EBITDA (TTM)
3.18BCNY477.13M · vs all stocks (USD)
Net Income (TTM)
2.68BCNY401.45M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
41.20%vs Biotechnology peers
Operating Cash Flow (TTM)
2.67BCNY400.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.55BCNY232.62M · vs all stocks (USD)
Forward Annual Dividend Rate
1.20CNYUpdated Oct 24, 2026Forward Annual Dividend Yield
1.36%vs all stocks
Trailing Annual Dividend Rate
1.20CNYUpdated Oct 24, 2026Trailing Annual Dividend Yield
1.36%vs all stocks
Payout Ratio
16.84%vs Biotechnology peers
Revenue
5.19BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
164.58MCNYFY2025 · Dec 31, 2025Gross Profit
5.02BCNYFY2025 · Dec 31, 2025Operating Income
2.48BCNY371.88M · vs all stocks (USD)
Pre-tax Income
2.54BCNYFY2025 · Dec 31, 2025Income Tax Expense
355.83MCNYFY2025 · Dec 31, 2025Net Income
2.19BCNYFY2025 · Dec 31, 2025EBIT
2.55BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.55BCNYFY2025 · Dec 31, 2025Research & Development
413.37MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.40BCNYFY2025 · Dec 31, 2025Other Operating Expenses
70.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
54.49MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
130.20KCNYFY2025 · Dec 31, 2025EPS (Basic)
4.86CNYFY2025 · Dec 31, 2025EPS (Diluted)
4.86CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
450.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
450.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.19BCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.11BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.93BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
445.72MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.19BCNYFY2025 · Dec 31, 2025Stock-based Compensation
25.43MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-42.16MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-13.63MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-46.89MCNYFY2025 · Dec 31, 2025Capital Expenditures
-186.00MCNYFY2025 · Dec 31, 2025Sale of Investments
92.90MCNYFY2025 · Dec 31, 2025Other Investing Activity
-1.94BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.04BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-360.00MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.02MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-363.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
450.00MSharesUpdated Oct 24, 2026Float Shares
224.78MSharesUpdated Oct 24, 2026% Held by Insiders
53.97%vs all stocks
% Held by Institutions
11.80%vs all stocks
Total Cash (MRQ)
4.24BCNY635.56M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.42CNYUpdated Oct 24, 2026Total Debt (MRQ)
4.26MCNY638.12K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0005xvs Biotechnology peers
Current Ratio (MRQ)
5.37xvs Biotechnology peers
Book Value per Share (MRQ)
18.80CNYUpdated Oct 24, 2026Total Assets
7.90BCNY1.18B · vs all stocks (USD)
Total Current Assets
4.17BCNYFY2025 · Dec 31, 2025Total Liabilities
821.48MCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.73BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
15.86MCNYFY2025 · Dec 31, 2025Total Current Liabilities
805.62MCNYFY2025 · Dec 31, 2025Cash
671.22MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.32MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
674.54MCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.51BCNYFY2025 · Dec 31, 2025Accounts Receivable
375.60MCNYFY2025 · Dec 31, 2025Inventory
71.66MCNYFY2025 · Dec 31, 2025Accounts Payable
102.72MCNYFY2025 · Dec 31, 2025Short-term Debt
1.87MCNYFY2025 · Dec 31, 2025Long-term Debt
2.01MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
3.27MCNYFY2025 · Dec 31, 2025Common Stock (Book)
450.00MCNYFY2025 · Dec 31, 2025Retained Earnings
3.01BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.08BCNY1.06B · vs all stocks (USD)
52-Week Low
75.55CNYUpdated Oct 24, 202652-Week High
138.30CNYUpdated Oct 24, 202652-Week Change
-22.17%vs all stocks
Beta
0.0020xvs all stocks
50-Day MA
104.12CNYUpdated Oct 24, 2026200-Day MA
100.68CNYUpdated Oct 24, 2026Avg 10-Day Volume
10.20MSharesUpdated Oct 24, 2026Avg 30-Day Volume
7.51MSharesUpdated Oct 24, 2026Diluted EPS (TTM)
5.94CNYUpdated Oct 24, 202618 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 48.4%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.48Industry median: -0.24Industry P95: 0.38Peers compared: 184
Profit margin is 43.7%, higher than 95% of its Biotechnology peers (median -34%)Significant
Profit margin: 0.44Industry median: -0.34Industry P95: 0.39Peers compared: 184
Return on equity is 36.7%, higher than 95% of its Biotechnology peers (median -22.2%)Significant
Return on equity: 0.37Industry median: -0.22Industry P95: 0.23Peers compared: 184
Return on assets is 20.3%, higher than 95% of its Biotechnology peers (median -19%)Significant
Return on assets: 0.20Industry median: -0.19Industry P95: 0.19Peers compared: 184
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 184
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.83
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.94B, above the global median of $1.15BNotable
Market cap (USD): 5,942,944,980Global Median: 1,150,342,212.262
Revenue is $919.21M, above the global median of $559.35MNotable
Revenue (USD): 919,207,219.517Global Median: 559,350,010.583
Levered free cash flow is $232.62M, above the global median of $18.98MNotable
Levered free cash flow (USD): 232,622,295.933Global Median: 18,979,762.15
Companies that share the same coordination system — how they create, deliver, or capture value.
CG Oncology, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Liquidia Corporation
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Getinge AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cogent Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Bochuan Electronic Co., Ltd.
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And EquityMulti-Year FCF With Growth And Margin
NVIDIA Corporation
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Classys Inc.
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And EquityMulti-Year FCF With Growth And Margin